Enhancement of in vivo and in vitro immune functions by a conformationally biased, response-selective agonist of human C5a: implications for a novel adjuvant in vaccine design.

Enhancement of in vivo and in vitro immune functions by a conformationally biased, response-selective agonist of human C5a: implications for a novel adjuvant in vaccine design.

Item
http://www.wikidata.org/entity/Q37461020
Innate immune induction and influenza protection elicited by a response-selective agonist of human C5aA novel adjuvant for vaccine development in the agedNovel strategies to enhance vaccine immunity against coccidioidomycosis.Control of methicillin resistant Staphylococcus aureus infection utilizing a novel immunostimulatory peptide.An agonist of human complement fragment C5a enhances vaccine immunity against Coccidioides infection.Preliminary evidence that the novel host-derived immunostimulant EP67 can act as a mucosal adjuvant.Targeting macrophage activation for the prevention and treatment of Staphylococcus aureus biofilm infections.Progress Toward a Human Vaccine Against CoccidioidomycosisComplement in immune and inflammatory disorders: therapeutic interventions.A novel C5a-derived immunobiotic peptide reduces Streptococcus agalactiae colonization through targeted bacterial killing.Complement in cancer: untangling an intricate relationship.
P2860

Enhancement of in vivo and in vitro immune functions by a conformationally biased, response-selective agonist of human C5a: implications for a novel adjuvant in vaccine design.

Item
http://www.wikidata.org/entity/Q37461020
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 15 October 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Enhancement of in vivo and in ...... el adjuvant in vaccine design.
@en
Enhancement of in vivo and in ...... el adjuvant in vaccine design.
@nl
type
label
Enhancement of in vivo and in ...... el adjuvant in vaccine design.
@en
Enhancement of in vivo and in ...... el adjuvant in vaccine design.
@nl
prefLabel
Enhancement of in vivo and in ...... el adjuvant in vaccine design.
@en
Enhancement of in vivo and in ...... el adjuvant in vaccine design.
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P577
P5875
P698
P921
P932
P356
P1433
P1476
Enhancement of in vivo and in ...... el adjuvant in vaccine design.
@en
P2093
P2860
P304
P31
P356
10.1016/J.VACCINE.2009.10.029
P407
P433
P478
P577
P5875
P698
P921
P932